CECAD Microsite

Anna Schmitt´s paper on ATM-deficient pancreatic cancer is now online


In a collaboration, led by Alexander Kleger (Ulm), Anna contributed data, which provide a preclinical rational for the use of PARP inhibitors in ATM-defective human PDAC.

Pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge, as the disease is typically diagnosed at an advanced stage, which frequently precludes curative local therapy. Moreover, PDAC is typically not very sensitive against chemotherapy. Thus, novel treatment approaches have to be identified. In the current manuscript, on which Anna Schmitt is a shared first author, the team provides data suggesting that particularly ATM-defective PDAC responds favorably to a combination consisting of PARP inhibitors and genotoxic chemotherapy.